IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?

References

• Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98–107.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2010;17:314–321.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54:2134–2144.
   PubMed Web of Science ®Google Scholar
• Liao KP, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:45–52.
   PubMed Web of Science ®Google Scholar
• Murdoch C, Muthana M, Lewis CE. Hypoxia regulates macrophage functions in inflammation. J Immunol. 2005;175:6257–6263.
   PubMed Web of Science ®Google Scholar
• Burke B, Giannoudis A, Corke KP, et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol. 2003;163:1233–1243.
   PubMed Web of Science ®Google Scholar
• Eguchi K, Manabe I. Macrophages and islet inflammation in type 2 diabetes. Diabetes Obes Metab. 2013;15:152–158.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Ikejima T, Warner SJ, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1in rabbits in vivo and in human mononuclear cells in vitro. J Immunol. 1987;139:1902–1910.
   PubMed Web of Science ®Google Scholar
• Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–265.
   PubMed Web of Science ®Google Scholar
• Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003–1018.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Overview of the interleukin-1 family of ligands and receptors. Semin Immunol. 2013;25:389–393.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Carubbi F, et al. The role of IL-1β in the bone loss during rheumatic diseases. Mediators Inflamm. 2015;2015:782382.
   PubMed Web of Science ®Google Scholar
• Strand V, Kavanaugh AF. The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxford). 2004;43:iii10–iii16.
   PubMedGoogle Scholar
• Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum. 2001;30:1–6.
   PubMed Web of Science ®Google Scholar
• van den Berg WB, Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I. Baillieres Best Pract Res Clin Rheumatol. 1999;13:577–597.
   PubMed Web of Science ®Google Scholar
• Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol. 1998;2:466–471.
   PubMed Web of Science ®Google Scholar
• Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology. 2002;41:972–980.
   PubMed Web of Science ®Google Scholar
• Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis. 2002;61:ii84–86.
   PubMed Web of Science ®Google Scholar
• Ghivizzani SC, Kang R, Georgescu HI, et al. Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol. 1997;1:3604–3612.
   Google Scholar
• Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000;191:313–320.
   PubMed Web of Science ®Google Scholar
• Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000;43:250–258.
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000;43:259–269.
   PubMed Web of Science ®Google Scholar
• Joosten LA, Helsen MM, van de Loo FA, et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis Rheum. 2008;58:S110–S122.
   Google Scholar
• Joosten LA, Helsen MM, Saxne T, et al. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol. 1999;163:5049–5055.
   PubMed Web of Science ®Google Scholar
• Makarov SS, Olsen JC, Johnston WN, et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A. 1996;93:402–406.
   PubMed Web of Science ®Google Scholar
• Otani K, Nita I, Macaulay W, et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol. 1996;156:3558–3562.
   PubMed Web of Science ®Google Scholar
• Müller-Ladner U, Roberts CR, Franklin BN, et al. Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. J Immunol. 1997;158:3492–3498.
   PubMed Web of Science ®Google Scholar
• Li J, Hsu HC, Mountz JD. Managing macrophages in rheumatoid arthritis by reform or removal. Curr Rheumatol Rep. 2012;14:445–454.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–686.
   PubMed Web of Science ®Google Scholar
• Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–969.
   PubMed Web of Science ®Google Scholar
• Tsai S, Santamaria P. MHC class II polymorphisms, autoreactive T-cells, and autoimmunity. Front Immunol. 2013;4:321.
   PubMed Web of Science ®Google Scholar
• Chen G. Immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells. Arch Immunol Ther Exp (Warsz). 2010;58:27–36.
   PubMed Web of Science ®Google Scholar
• Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev. 2009;1:CD005121.
   Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Canakinumab in CAPS study group: use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425.
   PubMed Web of Science ®Google Scholar
• Alten R, Gram H, Joosten LA, et al. The human anti-IL-1beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R67.
   PubMed Web of Science ®Google Scholar
• Alten R, Gomez-Reino J, Durez P, et al. Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord. 2011;12:153.
   PubMed Web of Science ®Google Scholar
• Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110:851–860.
   PubMed Web of Science ®Google Scholar
• Welsh N, Cnop M, Kharroubi I, et al. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Diabetes. 2005;54::3238–3244.
   PubMed Web of Science ®Google Scholar
• Zhou R, Tardivel A, Thorens B. et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010 Feb;11(2):136–140. doi:10.1038/ni.1831. Epub 2009 Dec 20.
   PubMed Web of Science ®Google Scholar
• Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol. 2010;11:897–904.
   PubMed Web of Science ®Google Scholar
• Akter R, Cao P, Noor H, et al. Islet amyloid polypeptide: structure, function, and pathophysiology. J Diabetes Res. 2016;2016:2798269.
   PubMed Web of Science ®Google Scholar
• Prajapati B, Jena PK, Rajput P, et al. Understanding and modulating the toll like receptors (TLRs) and NOD like receptors (NLRs) cross talk in type 2 diabetes. Curr Diabetes Rev. 2014;10:190–200.
   PubMedGoogle Scholar
• Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science. 2010;327:296–300.
   PubMed Web of Science ®Google Scholar
• Böni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab. 2008;93:4065–4074.
   PubMed Web of Science ®Google Scholar
• Boni-Schnetzler M, Boller S, Debray S, et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology. 2009;150:5218–5229.
   PubMed Web of Science ®Google Scholar
• Maedler K, Sergeev P, Ehses JA, et al. Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets. Proc Natl Acad Sci USA. 2004;101:8138–8143.
   PubMed Web of Science ®Google Scholar
• Donath MY, Gross DJ, Cerasi E, et al. Hyperglycemia-induced β-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes. 1999;48:738–744.
   PubMed Web of Science ®Google Scholar
• Quan W, Jo EK, Lee MS. Role of pancreatic β-cell death and inflammation in diabetes. Diabetes Obes Metab. 2013;15:141–151.
   PubMed Web of Science ®Google Scholar
• Akira S, Misawa T, Satoh T, et al. Macrophages control innate inflammation. Diabetes Obes Metab. 2013;15:10–18.
   PubMed Web of Science ®Google Scholar
• Banaei-Bouchareb L, Peuchmaur M, Czernichow P, et al. A transient microenvironment loaded mainly with macrophages in the early developing human pancreas. J Endocrinol. 2006;188:467–480.
   PubMed Web of Science ®Google Scholar
• Riley KG, Pasek RC, Maulis MF, et al. Macrophages are essential for CTGF-mediated adult β-cell proliferation after injury. Mol Metab. 2015;4:584–591.
   PubMed Web of Science ®Google Scholar
• Hume DA, Halpin D, Charlton S, et al. The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80. Macrophages of endocrine organs. Proc Natl Acad Sci USA. 1984;81:4174–4177.
   PubMed Web of Science ®Google Scholar
• Eguchi K, Manabe I, Oishi-Tanaka Y, et al. Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab. 2012;15:518–533.
   PubMed Web of Science ®Google Scholar
• Dasu MR, Devaraj S, Jialal I. High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab. 2007;293:E337–E346.
   Web of Science ®Google Scholar
• Lee HM, Kim JJ, Kim HJ, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013 Jan;62(1):194–204.
   PubMed Web of Science ®Google Scholar
• El Muayed M, Billings LK, Raja MR, et al. Acute cytokine-mediated downregulation of the zinc transporter ZnT8 alters pancreatic beta-cell function. J Endocrinol. 2010;206:159–169.
   PubMed Web of Science ®Google Scholar
• Maedler K, Schumann DM, Sauter N, et al. Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes. 2006;55:2713–2722.
   PubMed Web of Science ®Google Scholar
• Schumann DM, Maedler K, Franklin I, et al. The Fas pathway is involved in pancreatic beta cell secretory function. Proc Natl Acad Sci USA. 2007;104:2861–2866.
   PubMed Web of Science ®Google Scholar
• Suarez-Pinzon W, Sorensen O, Bleackley RC, et al. Beta-cell destruction in NOD mice correlates with Fas (CD95) expression on beta-cells and proinflammatory cytokine expression in islets. Diabetes. 1999;48:21–28.
   PubMed Web of Science ®Google Scholar
• Eizirik DL, Sandler S, Welsh N, et al. Interleukin-1 beta-induced stimulation of insulin release in mouse pancreatic islets is related to diacylglycerol production and protein kinase C activation. Mol Cell Endocrinol. 1995;111:159–165.
   PubMed Web of Science ®Google Scholar
• Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17:1481–1489.
   PubMed Web of Science ®Google Scholar
• Skeldon AM, Faraj M, Saleh M. Caspases and inflammasomes in metabolic inflammation. Immunol Cell Biol. 2014;92:304–313.
   PubMed Web of Science ®Google Scholar
• Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13:465–476.
   PubMed Web of Science ®Google Scholar
• Moran A, Bundy B, Becker DJ, et al. AIDA Study Group: interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381:1905–1915.
   PubMed Web of Science ®Google Scholar
• Koné-Paut I, Galeotti C. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol. 2015;11:1083–1092.
   PubMed Web of Science ®Google Scholar
• Koné-Paut I, Galeotti C. Anakinra for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol. 2014;10:7–18.
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517–1526.
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32:1663–1668.
   PubMed Web of Science ®Google Scholar
• Ehses JA, Lacraz G, Giroix MH, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA. 2009;106:13998–14003.
   PubMed Web of Science ®Google Scholar
• Sauter NS, Schulthess FT, Galasso R, et al. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology. 2008;149:2208–2218.
   PubMed Web of Science ®Google Scholar
• van Asseldonk EJP, Stienstra R, Koenen TB, et al. Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2011;96:2119–2126.
   PubMed Web of Science ®Google Scholar
• van Poppel PC, van Asseldonk EJ, et al. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes Metab. 2014;16:1269–1273.
   PubMed Web of Science ®Google Scholar
• Roell MK, Issafras H, Bauer RJ, et al. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem. 2010;285:20607–20614.
   PubMed Web of Science ®Google Scholar
• Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012;35:1654–1662.
   PubMed Web of Science ®Google Scholar
• Rissanen A, Howard CP, Botha J, et al. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab. 2012;14:1088–1096.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126:2739–2748.
   PubMed Web of Science ®Google Scholar
• Osiri M, Sattayasomboon Y. Prevalence and out-patient medical costs of comorbid conditions in patients with rheumatoid arthritis. Joint Bone Spine. 2013;80:608–612.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Di Benedetto P, et al. Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3 (NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. Clin Exp Immunol. 2015;182:35–44.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Cantarini L, et al. Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. J Med Case Rep. 2015;9:123.
   PubMedGoogle Scholar
• Missler-Karger B, Leu M, Raboisson MA, et al. FRI0219 Disease severity, no steroid use and type ii diabetes predict response to anakinra (kineret(R)) in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72:447.
   Web of Science ®Google Scholar